Merck (MRK) Declines More Than Market: Some Information for Investors

Company Performance - Merck's stock closed at $87.61, reflecting a -1.34% change from the previous day's closing price, underperforming the S&P 500 which lost 0.38% [1] - Over the past month, Merck's stock has increased by 5.6%, outperforming the Medical sector's gain of 2.72% and the S&P 500's gain of 4.06% [1] Upcoming Earnings - Merck is set to release its earnings report on October 30, 2025, with an expected EPS of $2.37, representing a 50.96% increase from the same quarter last year [2] - The consensus estimate for revenue is $17.19 billion, indicating a 3.18% increase from the same quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates predict earnings of $8.93 per share and revenue of $64.93 billion, reflecting changes of +16.73% and +1.19% respectively compared to the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Merck may indicate shifting business dynamics, with positive revisions suggesting optimism about the company's outlook [3][4] Zacks Rank and Valuation - Merck currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 9.94, which is below the industry average Forward P/E of 14.65 [5] - The company has a PEG ratio of 0.91, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.59 [6] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 21, placing it in the top 9% of over 250 industries [6][7]